We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.
- Authors
Wang, Tao; Denman, Desirée; Bacot, Silvia M.; Feldman, Gerald M.
- Abstract
While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-(L)1 immunotherapy. Recent studies using patient blood samples to assess immunotherapeutic responsiveness suggests a promising approach to the identification of novel and/or improved biomarkers for anti-PD-(L)1 immunotherapy. In this review, we discuss the advances in our evolving understanding of the regulation and function of PD-L1 expression, which is the foundation for developing blood-based PD-L1 as a biomarker for anti-PD-(L)1 immunotherapy. We further discuss current knowledge and clinical study results for biomarker identification using PD-L1 expression on tumor and immune cells, exosomes, and soluble forms of PD-L1 in the peripheral blood. Finally, we discuss key challenges for the successful development of the potential use of blood-based PD-L1 as a biomarker for anti-PD-(L)1 immunotherapy.
- Subjects
PROGRAMMED death-ligand 1; BIOMARKERS; IMMUNOTHERAPY; IMMUNE checkpoint inhibitors
- Publication
Biomedicines, 2022, Vol 10, Issue 5, p1181
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines10051181